Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence

Jiansong Xu, Hedy Kober, Xin Wang, Elise E. DeVito, Kathleen M. Carroll, Marc N. Potenza

Article history:
Received 25 April 2014
Received in revised form 6 July 2014
Accepted 7 July 2014
Available online 17 July 2014

Keywords:
Addiction
Neuroimaging
Treatment outcome
Brain volume
Hippocampus
Substance use disorder

ABSTRACT

Background: Data suggest that the amygdala and hippocampus contribute to cocaine seeking and use, particularly following exposure to cocaine-related cues and contexts. Furthermore, indices of pre-treatment cocaine-use severity have been shown to correlate with treatment outcome in cocaine-dependent patients.

Methods: The aim of this study was to assess the relationships between amygdalar and hippocampal volumes and cocaine use before and during treatment. High-resolution magnetic-resonance brain images were obtained from 23 cocaine-dependent patients prior to treatment and 54 healthy comparison individuals. Automated segmentation of the amygdala and hippocampus images was performed in FreeSurfer. Cocaine-dependent patients subsequently received behavioral therapy alone or combined with contingency management as part of a treatment trial, and cocaine-use indices (self-report, urine toxicology) were collected.

Results: Comparison participants and cocaine-dependent patients did not show significant difference in amygdalar and hippocampal volumes at pre-treatment. Within the patient group, greater hippocampal volumes were correlated with more days of cocaine use before treatment and with poorer treatment outcome as indexed by shorter durations of continuous abstinence from cocaine and lower percentages of cocaine-negative urine samples during treatment. Mediation analysis indicated that pre-treatment hippocampal volumes mediated the relationships between pre-treatment cocaine use and treatment outcomes.

Conclusions: The finding of a significant correlation between hippocampal volume and pre-treatment cocaine-use severity and treatment response suggests that hippocampal volume should be considered when developing individualized treatments for cocaine dependence.

© 2014 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

An important goal of clinical research involves identifying predictors of treatment response and their underlying clinical and neural mechanisms, in order to improve treatment outcomes (Donovan et al., 2013; McKay et al., 2001; Potenza et al., 2011; Reiber et al., 2002). In the context of cocaine addiction, severity of pre-treatment cocaine use has been one of the measures most consistently related to cocaine use both during and after treatment (Ahmadi et al., 2006, 2009; Carroll et al., 1993; Ciraulo et al., 2003; Poling et al., 2007; Reiber et al., 2002) and to treatment attrition (Alterman et al., 1996; Kampman et al., 2001). However, the mechanism for these relationships are yet unknown, and to our knowledge, the neural mechanisms that underlie them have not been explored.

Models of addiction recognize the amygdala and hippocampus as having key roles in the development and maintenance of addiction (Volkow et al., 2004, 2011). Humans and animals form strong long-term memories of context-response–drug associations after repeated administration of cocaine or other addictive drugs (Buffalari and See, 2010; Crombag et al., 2008). The amygdala and
hippocampus each play critical roles in the formation, retrieval, and reconsolidation of such long-term memories. Thus, these regions may contribute to drug-seeking and drug-using behaviors after exposure to stress, cocaine priming, or cocaine-related cues in cocaine-addicted humans and rats (Crombag et al., 2008; Fuchs et al., 2007, 2005; See, 2005; Shaham et al., 2003). For example, exposure to cocaine-related cues increases neural activity and expression of c-fos, a neuronal activity marker, in the amygdala and hippocampus in rats previously treated with cocaine (Brown et al., 1992; Carelli, 2002; Mead et al., 1999; Miller and Marshall, 2004). In addition, lesioning or pharmacological inactivation of either the amygdala or hippocampus attenuates relapse to cocaine-seeking behavior triggered by stress, cocaine priming, or cocaine-related cues (Belujon and Grace, 2011; Fuchs et al., 2007; Gardner, 2011; Grimm and See, 2000; McLaughlin and See, 2003). Findings that amygdalar or hippocampal inactivation or disconnection attenuates relapses to drug-seeking behavior following exposure to cocaine-related cues suggest impaired activation or reconsolidation of long-term memories of context–response–drug associations (Fuchs et al., 2009; Ramirez et al., 2009; Wells et al., 2011).

Consistent with these findings from animal studies, human neuroimaging studies report that stress- or drug cue–induced craving for cocaine use is associated with increased activation in the amygdala, hippocampus, and other brain regions in cocaine-dependent patients (Childress et al., 2008, 1999; Kilts et al., 2001; Kilts et al., 2004; Kober et al., 2008; Potenza et al., 2012; Prisciandaro et al., 2011; Wilcox et al. 2011; Valachkov et al., 2012). Therefore, amygdalar and hippocampal function in cocaine-dependent patients may contribute importantly to long-term memories of context–response–drug associations and to cravings for cocaine use after exposure to stress or cocaine-related cues.

Further, both human and animal studies indicate that chronic cocaine use alters the structure and function of multiple brain regions. For example, chronic cocaine administration reduces neurogenesis in the hippocampus of adult rats (Dominguez-EScriba et al., 2006; Garcia-Fuster et al., 2011; Noonan et al., 2008; Sudai et al., 2011; Yamaguchi et al., 2005). Several human neuroimaging studies have found reduced gray-matter volumes in the prefrontal cortex of cocaine-dependent patients relative to healthy comparison participants (Alia-Klein et al., 2011; Ersche et al., 2011; Mackey and Paulus, 2013). However, findings regarding the volumes of the amygdala and hippocampus in cocaine-dependent patients are less consistent. One study reported increased volume in the amygdala (Ersche et al., 2012), several studies reported reduced volume in at least one of the two structures (Alia-Klein et al., 2011; Makris et al., 2004; Moreno-Lopez et al., 2012; Rando et al., 2013), and several studies did not find volumetric differences (Jacobson et al., 2001; Narayana et al., 2010; Sim et al., 2007; reviewed in Mackey and Paulus, 2013).

To investigate further whether the volumes of the amygdala and hippocampus are reduced in cocaine-dependent patients, and the potential role of the two brain structures in cocaine dependence, we used an automated approach to segment the amygdala and hippocampus in cocaine-dependent patients who were imaged just prior to initiating treatment. MRI data were also collected from healthy comparison subjects. Based on extant findings, we hypothesized that: (1) pre-treatment cocaine use would be associated with treatment outcome; and (2) amygdalar and hippocampal volumes would be smaller in patients relative to comparison subjects. We additionally hypothesized (hypothesis 3) that amygdalar and hippocampal volumes would correlate with cocaine use before and during treatment, although both positive and negative correlations were considered as reasonable hypotheses. Specifically, the smaller volumes predicted for cocaine-dependent might suggest that volumes would correlate inversely with drug use. Alternatively, given animal data that lesions to the amygdala or hippocampus may attenuate relapse, a positive correlation might be predicted.

### Table 1
Demographic information of healthy control participants and cocaine-dependent patients. Data are presented as mean (standard deviation) or as N (percent), as indicated.

<table>
<thead>
<tr>
<th></th>
<th>Healthy control N = 54</th>
<th>Cocaine patients N = 23</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (SD)</td>
<td>29.6 (10.1)</td>
<td>39.7 (8.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Education, years (SD)</td>
<td>14.9 (1.7)</td>
<td>12.0 (1.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Female, N (%)</td>
<td>32 (40.7)</td>
<td>6 (26.1)</td>
<td>.2</td>
</tr>
<tr>
<td>Cigarette Smokers, N (%)</td>
<td>5 (9.3%)</td>
<td>19 (82.6%)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Race/Ethnicity, N (%)</td>
<td>1 (1.9%)</td>
<td>2 (8.7%)</td>
<td>&lt;.01</td>
</tr>
</tbody>
</table>

### Table 2
Clinical characteristics of cocaine-dependent patients. Data are presented as mean (standard deviation) or as N (percent), as indicated.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cocaine-dependent patients n = 23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never married/Living alone, N (%)</td>
<td>16 (60.5)</td>
</tr>
<tr>
<td>Unemployed, N (%)</td>
<td>19 (62.2)</td>
</tr>
<tr>
<td>Total number of months incarcerated, lifetime</td>
<td>32.8 (48.8)</td>
</tr>
<tr>
<td>Lifetime psychiatric diagnoses, N (%)</td>
<td>15 (65.2)</td>
</tr>
<tr>
<td>Alcohol-use disorder</td>
<td>6 (21.1)</td>
</tr>
<tr>
<td>Major depression</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Anxiety disorder</td>
<td>0 (0)</td>
</tr>
<tr>
<td>History of substance use</td>
<td>14.6 (7.2)</td>
</tr>
<tr>
<td>Days of cocaine use in 28 days prior to treatment</td>
<td>7.1 (3.0)</td>
</tr>
<tr>
<td>Years of regular cocaine use, lifetime</td>
<td>8.2 (5.5)</td>
</tr>
</tbody>
</table>
participants also met thrice weekly with an independent clinical evaluator who collected urine and breath samples, and monitored clinical symptoms.

In addition to CBT, 12 (52.2%) cocaine-dependent patients also received contingency management (CM). During CM, chances to draw prizes from a bowl were contingent on treatment adherence (e.g., CBT homework completion) or verified abstinence (submission of cocaine-negative urine specimens), and draws were earned in an escalating schedule using procedures described previously (Ledgerwood and Petry, 2006; Petry, 2000; Petry et al., 2000).

2.3. Clinical assessments and treatment outcome indices

Participants were assessed before treatment, weekly during treatment, and at the 12-week treatment-termination point using the Substance Abuse Calendar which uses the Timeline-Follow-Back method (Fals-Stewart et al., 2000; Hersh et al., 1999) to collect detailed day-by-day self-reports of drug and alcohol use, as described previously (Carroll et al., 2008). Substance-related problems were assessed at pre-treatment and post-treatment using the Addiction Severity Index (ASI; McLellan et al., 1992). Urine samples were collected three times each week and tested for cocaine, opioids, stimulants, marijuana and benzodiazepines. Data from all samples were used in the analyses presented. The percent of negative urine samples was over all submitted urine samples, and missing samples were not included in calculation. Primary treatment outcome measures included self-reported longest duration of continuous cocaine abstinence (urine-confirmed) during the 84-day active-treatment period and percentage of cocaine-negative urine samples during treatment, as in prior studies (Brewer et al., 2008; Xu et al., 2010).

2.4. Image acquisition and processing

All MRI images were acquired within one week before treatment. High-resolution T1-weighted anatomical images were acquired using a 3-T scanner (Siemens Trio) with the following parameters: TR = 1,500 ms, TE = 2.83 ms, flip angle = 7°, FOV = 256 × 256 mm², matrix = 256 × 256, 1 mm³ isotropic voxels, 176 slices. The hippocampus and amygdala were automatically segmented using FreeSurfer version 5.1.0 (http://www.surfer.nmr.mgh.harvard.edu; Dale et al., 1999; Fischl and Dale, 2000; Fischl et al., 2001). Automated FreeSurfer segmentation is valid and reliable (Dworak et al., 2011; Morey et al., 2009). Segmentation of subcortical structures is based on a probabilistic atlas provided by FreeSurfer. The atlas is created by the Center for Morphometric Analysis from 20 unrelated, randomly selected healthy people. The detailed procedure has been described previously (Fischl et al., 2002). In brief, FreeSurfer scripts autorecon1, 2, and 3 were run in sequence on all imaging data. Processing consisted of removal of non-brain tissue, Talairach transformation, segmentation of subcortical volumetric structures including hippocampus and amygdala, intensity normalization, tessellation of the gray-matter/white-matter boundary, and labeling of each voxel based on previous probabilistic information. Intracranial volume (ICV) was generated during this processing.

2.5. Data analyses

SPSS Version 19 was used in analyses of volumetric and clinical data. General Linear Model Univariate was used to assess between-group differences in amygdalar and hippocampal volumes with diagnostic group (cocaine-dependent, healthy comparison) included as a between-subject factor and age, gender, and ICV (which did not differ between groups) included as covariates. Within the cocaine-dependent group, partial correlations were used to assess the relationships between pre-treatment and within-treatment cocaine-use indicators and amygdalar and hippocampal volumes separately for each pair, controlling for effects of ICV, age, gender, and different treatments (i.e., CBT only versus CBT + CM).

2.6. Mediation analysis

Given correlations between (1) pre-treatment cocaine use and treatment outcome, (2) pre-treatment cocaine use and hippocampal volume, and (3) hippocampal volume and treatment outcome, a mediation analysis was used to examine the extent to which hippocampal volume mediated the relationship between pre-treatment cocaine use and treatment outcome. Mediation analyses test whether the relationship between any two variables (e.g., pre-treatment drug use and treatment outcome) can be explained by the values from a third variable (e.g., hippocampal volume). If hippocampal volume is a full mediator of the pre-treatment versus within-treatment cocaine use relationship, then the direct association between the two variables will become non-significant when the model controls for hippocampal volume. The mediation analysis used here applied the standard three-variable path model (Shrout and Bolger, 2002) and a bootstrapping test for the statistical significance of the model (Shrout and Bolger, 2002), following our prior work (Kober et al., 2008, 2010). This approach to mediation analysis presumes associations between all three variables under test. As such, any hypothesized relationships (e.g., mediation of pre- and within-treatment cocaine use by amygdalar volume) that did not show the necessary significant correlations were not included in formal mediation analyses. Hippocampal volume, days of cocaine use in a month prior to treatment, and treatment outcome (percent cocaine-negative urine samples during treatment) were correlated, and therefore, were subjected to mediation analyses. Given that both sides of the hippocampus were correlated with the other variables, and were linearly related to outcome measures, this structure served as a mediator in the relationship between pre-treatment cocaine use and treatment outcome.
highly inter-correlated, we collapsed across hemispheres to create an “average” volume.

3. Results

Relative to the group receiving CBT only, the patient subgroup receiving CBT plus CM had a significantly longer duration of abstinence ($t = 2.3$, $df = 21$, $p = .036$) and greater percentage of cocaine-negative urine samples ($t = 3.3$, $df = 21$, $p = .003$). However, the two patient subgroups showed similar correlations between their pre-treatment and within-treatment indices of cocaine use, and between these indices and volumes of the amygdala and hippocampus (Figs. 1 and 2). Therefore, subsequent analyses combine all cocaine-dependent patients into one group, including different treatments as a covariate. In investigating the relationship between clinical variables (hypothesis 1), we found that more days of pre-treatment cocaine use were negatively associated with abstinence within treatment (i.e., lower percentage of cocaine-negative urine samples ($r = -.54, p = .02$) and fewer maximum days of continuous abstinence from cocaine ($r = -.46, p = .05$; Fig. 1A, B)), after controlling for age, gender, and different treatments (with or without CM). These relationships were still significant after correcting for multiple ($n = 2$) analyses using a false-discovery-rate (FDR) algorithm.

Table 3 shows the volumes of the amygdala and hippocampus. Healthy participants and cocaine-dependent patients did not show significant differences in volumes of the amygdala and hippocampus, after controlling for age, gender, and IV, and this finding did not support our hypothesis of reduced volumes in patients.

Within the cocaine-dependent patients, we found significant positive correlations between hippocampal volumes and cocaine-use measures, consistent with hypothesis 3. Specifically, more days of self-reported cocaine use within the 28 days before enrollment into the clinical trial were associated with greater hippocampal volumes after controlling for ICV, age, and gender (Fig. 1C, 1D). In turn, greater hippocampal volumes were associated with poorer treatment outcomes, measured by lower percentages of cocaine-negative urine samples and shorter durations of maximum consecutive days of cocaine-abstinence during treatment (negative correlation; Fig. 2, Table 4) after controlling for ICV, age, gender, and different treatments (i.e., CBT versus CBT+CM). These relationships remained significant after FDR correction for multiple analyses ($n = 12$).

These correlations could suggest one of two possible relationships between pre-treatment cocaine use, hippocampal volumes, and treatment outcomes. The first possibility is that pre-treatment cocaine use and hippocampal volume are independently related

### Table 3
Volumes of the amygdala and hippocampus in mm$^3$ (Mean (SD)).

<table>
<thead>
<tr>
<th></th>
<th>Amygdala</th>
<th>Hippocampus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Left</td>
<td>Right</td>
</tr>
<tr>
<td><strong>Healthy controls</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>($n=54$)</td>
<td>1725.9</td>
<td>1832.6</td>
</tr>
<tr>
<td><strong>Cocaine-dependent</strong></td>
<td>(274.2)</td>
<td>(257.3)</td>
</tr>
<tr>
<td>($n=23$)</td>
<td>1027.5</td>
<td>1746.6</td>
</tr>
<tr>
<td></td>
<td>(223.2)</td>
<td>(226.9)</td>
</tr>
</tbody>
</table>

### Table 4
Correlations between volumes of the amygdala and hippocampus and cocaine use before and during treatment.

<table>
<thead>
<tr>
<th>Cocaine Use Indicators</th>
<th>Amygdala Mean (SD)</th>
<th>Hippocampus Mean (SD)</th>
<th>Correlations ($r$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L</td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>Cocaine use days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before treatment</td>
<td>14.6 (7.2)</td>
<td>.419</td>
<td>.07</td>
</tr>
<tr>
<td>Longest abstinence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>during treatment</td>
<td>43.8 (27.4)</td>
<td>-.22</td>
<td>.05</td>
</tr>
<tr>
<td>% Negative urines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>during treatment</td>
<td>47.6 (14.1)</td>
<td>.05</td>
<td>.25</td>
</tr>
</tbody>
</table>

Cocaine use indicator descriptions: Cocaine use days before treatment: number of days of cocaine use within 28 days immediately before treatment onset; Longest abstinence during treatment: maximum number of days of continuous abstinence from cocaine during treatment; %Negative urines during treatment: percent of cocaine-negative urine samples during treatment. L=left, R=right. Correlations between cocaine use indicators and amygdalar and hippocampal volumes are presented as Pearson’s correlation coefficients ($r$) with significance levels indicated by *$p < .05$ and **$p < .01$ before correction for multiple analyses.
to (and possibly contribute to) treatment outcome. The second possibility is that the relationship between pre-treatment cocaine use and treatment outcome is mediated by pre-treatment hippocampal volume. To test these possibilities, we performed a formal mediation analysis that explicitly tested whether the relationship between pretreatment drug use and percentage of cocaine-negative urine samples during treatment was explained by participants’ pre-treatment hippocampal volume. We found that hippocampal volume fully mediated this relationship (Fig. 3), meaning that including hippocampal volume in the mediation model made the relationship between pre-treatment cocaine use and percent of cocaine-negative urine samples during treatment no longer statistically significant.

4. Discussion

The main findings were that: (1) pre-treatment cocaine use negatively correlated with cocaine abstinence during treatment; and (2) pre-treatment hippocampal volume positively correlated with cocaine use before and during treatment, and mediated the positive correlation between the two measures. However, cocaine-dependent and comparison subjects did not show significant differences in amygdalar and hippocampal volumes.

4.1. Hippocampal volume and cocaine use before and during treatment

As discussed in the introduction, several models of addictions implicate the amygdala and hippocampus in the maintenance of drug-taking behavior. Preclinical research indicates that the structure and function of the amygdala and hippocampus are important to cue-induced drug-seeking and drug-using behavior. It is possible that individuals with larger hippocampus may have greater hippocampal functional activities, form stronger long-term memories of context-response-drug associations after repeated administration of cocaine, experience more frequent and/or stronger craving for cocaine use in the environment with cocaine cues, and finally use cocaine more frequently. The current findings of significant correlations between hippocampal volume at treatment onset and both pre-treatment and within-treatment cocaine use are consistent with this prediction.

Another possible explanation for the positive correlation between hippocampal volume and cocaine use is gliosis in the hippocampus. Cocaine use may lead to gliosis in the hippocampus and increase its volume (Fattore et al., 2002; Narayana et al., 2010). Therefore, it is possible that more pre-treatment cocaine use may induce greater gliosis and generate larger hippocampal volumes, which may then predispose to poorer treatment outcome. Additionally, as previously proposed (Di Sclafani et al., 2002; Narayana et al., 2010), cocaine’s propensities to induce hippocampal gliosis may obscure effects of hippocampal neuronal loss. The results of the current study cannot identify which factor (e.g., greater hippocampal functional activity, greater gliosis in the hippocampus after cocaine use, or other factors) relates to more cocaine use as observed in the current study. This issue should be addressed in the future studies, because different neuropathophysiological mechanisms underlying the positive correlations between hippocampal volume and severity of cocaine use may require different treatment strategies.

The current finding that, within our mediation model, hippocampal volume statistically fully mediated the relationship between pre-treatment and within-treatment cocaine use indicates that the correlation between pre-treatment and within-treatment cocaine use becomes non-significant after accounting for individual variation in hippocampal volume. However, it does not demonstrate causality and does not preclude the possibility of additional factors (that were not included in our model) also mediating this relationship, nor does it demonstrate a change during treatment. Further investigation should directly test whether hippocampal volume changes during treatment in accordance with changes in drug use.

The current hippocampal findings also do not indicate that the hippocampus is the only brain structure that may link pre-treatment and within-treatment cocaine use. Subcortical structures such as the amygdala, hippocampus, and their output target nucleus accumbens are regulated by top-down executive control from the frontoparietal cortex (Banich et al., 2009; Corbetta et al., 2008; Hollmann et al., 2012). It has been proposed that these subcortical structures may exert a greater influence on human behavior if the top-down executive control is reduced due to the impairment of the frontoparietal cortex (Everitt and Robbins, 2005; Volkow et al., 2011). Chronic cocaine use alters multiple extensive cortical and subcortical regions including the frontoparietal cortex and striatum. Therefore, reduced top-down executive control from the frontoparietal cortex and changed subcortical functional activity might relate importantly to cocaine use. Consistent with this view, cocaine use correlated with poorer white-matter integrity in extensive regions including corpus callosum and the frontal lobes (Xu et al., 2010) and with functional activity during a cognitive-control task (i.e., Stroop task), wherein task-related activity in a subcortical network involving the hippocampus, amygdala, striatum and thalamus correlated with urine-toxicology-assessed treatment outcomes (Brewer et al., 2008; Worhunsky et al., 2013). The relationships between integrity of brain structure other than hippocampus and amygdala and severity of cocaine use should be assessed in future studies.

4.2. Amygdalar and hippocampal volumes

As mentioned in the introduction, previous findings regarding the volumes of the hippocampus and amygdala in cocaine-dependent patients are not consistent. The current finding of no
significant difference between patients and healthy participants is consistent with the findings from the majority of previously published studies. Several factors could contribute to the inconsistent findings in literature, including small sample sizes, cocaine-use status (i.e., abstinent versus non-abstinent) and other clinical characteristics, and methods for measuring amygdalar and hippocampal volumes. These factors should be evaluated in future studies.

A notable limitation of this study is the small sample size with two different treatments (47.8% of the patients received “CBT only” while the remaining patients received “CBT plus CM”). However, the correlation between hippocampal volume, pre-treatment cocaine use, and percentage of cocaine-negative urine samples during treatment remained significant after controlling for different treatments.

4.3. Implications of the present findings

This is the first study to suggest that the often-found association between pre-treatment and within-treatment cocaine use is mediated by individual volumetric differences in a brain structure: the hippocampus. The current findings that larger hippocampal volumes are not only associated with poorer treatment outcome but also mediate the relationship between pre-treatment and within-treatment cocaine use have multiple implications for (1) a basic understanding of cocaine dependence, (2) the neural substrates underlying treatment effects, and (3) improving future treatments. Specifically, the findings suggest a possible neural mechanism that may underlie the relationship between pre-treatment and within-treatment cocaine use. If further studies provide additional support for this hypothesis, it would suggest that possible neuroprotective agents might be considered as an intervention to mitigate neurotoxic effects of cocaine on the hippocampus. As reviewed in the introduction, the hippocampus contributes importantly to the formation, retrieval, and reconsolidation of long-term memories of context-response–drug associations, and thus may contribute to cue-induced drug craving and drug use in cocaine-dependent patients (Crombag et al., 2008; Fuchs et al., 2007, 2005; See, 2005; Shahnam et al., 2003). Taken together with our current findings, it is possible that cocaine-dependent patients with larger hippocampal volumes may experience more frequent and/or stronger drug cravings in response to drug-cue environments or to drug-cue stimuli, and thus may fare worse in treatment, although this possibility remains speculative and warrants direct investigation. If this is the case, treatments like CBT that emphasize how to avoid drug-use cues and contexts and how to regulate cue-induced craving may benefit from augmentation with psychological or pharmacological strategies for enhancing cognitive control, although this possibility too warrants direct examination. Future studies should examine both hippocampal function and volume in relationship to treatment outcome in cocaine dependence.

In summary, the findings of hippocampal volumes correlating with both pre-treatment and within-treatment cocaine use and mediating the relationships between these measures, indicate an important role for the hippocampus in the treatment of cocaine dependence and suggest possible new avenues for treatment development.

Role of funding source

This study was funded by the following grants: National Institute on Drug Abuse (NIDA) grants K01 DA027750, P50 DA09241, R01 DA020908, P20DA027844, K12 DA00167, and R01 DA035058. EED was supported by K12 DA031050 from ORWH, NIDA, NIAAA and OD.

References


Contributors

Xu, Potenza, and Carroll designed the study, Xu, Kobier, and Wang analyzed the data, and all authors contributed to write the paper.


